The world is facing the threat of ‘superbugs’ as these bacteria dubbed as methicillin-resistant Staphylococcus aureus (MRSA) have evolved into one of the most difficult-to-treat pathogens. MRSA is a bacteria that is resistant to many antibiotics. In the external community, most MRSA infections are skin infections. In medical facilities, MRSA causes life-threatening bloodstream infections, pneumonia and surgical site infections. A new study suggests that treatment with the wrong antibiotic could make MRSA-induced infections worse.
BioDelivery Sciences International Inc recently announced that the U.S. Food and Drug Administration had approved its opioid treatment for chronic pain. Belbuca is an opioid film patch and aims to treat patients with chronic pain who need round-the-clock treatment and for whom current alternatives do not suffice. Belbuca has the advantages of lower possibility for abuse and less chance of causing constipation. Physicians will be able to prescribe the medication for 6 months at a time rather than by the month.